SonaCare Medical Accelerates the Expansion of its Commercialization Infrastructure

CHARLOTTE, N.C., May 13, 2014 /PRNewswire/ -- SonaCare Medical, LLC is experiencing significant growth of its FDA cleared Sonatherm® offering with sales to both major academic and luminary sites. To support its accelerating growth, the company has hired Tres Glenn, an experienced urology sales executive, to the newly created position of Director of Sales for the U.S. The impetus for this hire is to further capitalize on the growing demand for the company's new 510K cleared Sonatherm® Laparoscopic Surgical Ablation System. Beginning this summer, the company also plans to add sales and clinical support personnel in several core metropolitan areas to address the increasing demand for its new focused ultrasound offering.

Tres Glenn is an accomplished medical device executive with over a decade of experience in leading top performing sales and marketing teams at regional, national, and global levels. Most recently Tres served as VP and General Manager at UC-CARE where he led the early stage U.S. commercialization efforts of a prostate biopsy system. Prior to UC-CARE, Tres was the VP of Global Marketing at Galil Medical, a global leader in cryotherapy solutions for prostate and kidney cancer treatment, with primary call points in urology and interventional radiology. Tres has almost 20 years of experience in medical sales and holds a Bachelor of Political Science degree from Arizona State University.

"Since the launch of Sonatherm® in late 2013, SonaCare Medical has worked tirelessly to respond to the growing market demand for its innovative sound medicine products and applications in the U.S. market," said Mike Klein, CEO. "The addition of Tres and his demonstrated outstanding leadership and strategic commercialization skills will enable the company to increase revenue, accelerate growth, penetrate new markets, and introduce solution based offerings for our customers." 

"Tres's experience in building and leading high performing sales teams in the prostate and kidney ablation market makes him an important addition and provides us with increased capacity and expertise.  We see Tres playing an important role in the company," said Klein. "Tres will serve as a leader in our expanding commercialization infrastructure in targeted U.S. markets. Tres will serve as the domestic counterpart to Alex Gonzalez who plays a similar lead sales role in our international operations."

"I am excited to join such a vibrant and exciting company with genuinely game-changing technology," said Glenn. "I have always felt a strong commitment to bringing innovative medical solutions into our health system. As the oncologic landscape is changing and enhanced diagnostic tools lead to earlier detection, SonaCare's focused therapeutic ultrasound ablation systems provide a minimally invasive therapy option that is poised to have a dramatic impact in the market. I'm really passionate about this technology and look forward to getting started."

About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company, is a world leader in minimally-invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate^® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate^® 500, which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm^® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate^® 450 or 500. In the event Sonablate^® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S. SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C. www.SonaCareMedical.com

SOURCE SonaCare Medical, LLC